A two-phase strategy for treatment of oxidant-dependent cancers
- 31 December 2007
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 69 (3), 489-496
- https://doi.org/10.1016/j.mehy.2006.12.065
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Programmed cell death of stressed keratinocytes and its inhibition by vitamin D: The role of death and survival signaling pathwaysApoptosis, 2006
- Epigallocatechin‐3‐gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibilityJournal of Cellular Physiology, 2006
- EGF receptor–ligand interaction generates extracellular hydrogen peroxide that inhibits EGFR-associated protein tyrosine phosphatasesBiochemical and Biophysical Research Communications, 2005
- Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 Years LaterIntegrative Cancer Therapies, 2005
- Ligand-independent trans-Activation of the Platelet-derived Growth Factor Receptor by Reactive Oxygen Species Requires Protein Kinase C-δ and c-SrcOnline Journal of Public Health Informatics, 2002
- A threshold concept for cancer therapyMedical Hypotheses, 2000
- Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agentMedical Hypotheses, 1995
- High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior ChemotherapyThe New England Journal of Medicine, 1985
- Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced CancerThe New England Journal of Medicine, 1979
- Synergistic Killing of Ehrlich Ascites Carcinoma Cells by Ascorbate and 3-Amino-1,2,4,-triazoleOncology, 1969